GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, today announced it has closed on a Series A financing generating immediate proceeds of $157 million, led by Matrix Capital Management with participation by Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, and Novartis Venture Fund, and Seattle Children's Research Institute. The company's unique platform aspires to functionally cure autoimmune, alloimmune, autoinflammatory, and allergic diseases using novel technologies that precisely redirect stable, potent engineered Tregs to tissues damaged by abnormal immune responses. GentiBio, leveraging its highly differentiated platform, is able to create multiple, tunable Treg phenotypes from more abundant autologous and allogeneic cell sources that can be manufactured at scale. GentiBio has raised $177 million since 2020 to transcend technical hurdles that have limited the potential of therapeutic Tregs.